IL164652A0 - Method of treating arrhythmias comprising administration of an A1 adenosine agonist with a beta blocker, calcium channel blocker or a cardiac glycoside - Google Patents

Method of treating arrhythmias comprising administration of an A1 adenosine agonist with a beta blocker, calcium channel blocker or a cardiac glycoside

Info

Publication number
IL164652A0
IL164652A0 IL16465204A IL16465204A IL164652A0 IL 164652 A0 IL164652 A0 IL 164652A0 IL 16465204 A IL16465204 A IL 16465204A IL 16465204 A IL16465204 A IL 16465204A IL 164652 A0 IL164652 A0 IL 164652A0
Authority
IL
Israel
Prior art keywords
blocker
administration
calcium channel
cardiac glycoside
adenosine agonist
Prior art date
Application number
IL16465204A
Other languages
English (en)
Original Assignee
Cv Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cv Therapeutics Inc filed Critical Cv Therapeutics Inc
Publication of IL164652A0 publication Critical patent/IL164652A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
IL16465204A 2002-04-18 2004-10-18 Method of treating arrhythmias comprising administration of an A1 adenosine agonist with a beta blocker, calcium channel blocker or a cardiac glycoside IL164652A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37376602P 2002-04-18 2002-04-18
PCT/US2003/012043 WO2003088978A1 (en) 2002-04-18 2003-04-18 Method of treating arrhythmias comprising administration of an a1 adenosine agonist with a beta blocker, calcium channel blocker or a cardiac glycoside

Publications (1)

Publication Number Publication Date
IL164652A0 true IL164652A0 (en) 2005-12-18

Family

ID=29251078

Family Applications (1)

Application Number Title Priority Date Filing Date
IL16465204A IL164652A0 (en) 2002-04-18 2004-10-18 Method of treating arrhythmias comprising administration of an A1 adenosine agonist with a beta blocker, calcium channel blocker or a cardiac glycoside

Country Status (17)

Country Link
US (3) US7005425B2 (no)
EP (1) EP1494685B1 (no)
JP (1) JP2005530736A (no)
KR (1) KR20040106354A (no)
CN (2) CN1646142A (no)
AT (1) ATE418991T1 (no)
AU (1) AU2003235466C1 (no)
CA (1) CA2482928A1 (no)
DE (1) DE60325572D1 (no)
ES (1) ES2318129T3 (no)
IL (1) IL164652A0 (no)
MX (1) MXPA04010285A (no)
NO (1) NO20045005L (no)
NZ (1) NZ536001A (no)
RU (1) RU2332220C2 (no)
WO (1) WO2003088978A1 (no)
ZA (1) ZA200408411B (no)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE361667T1 (de) 1999-03-23 2007-06-15 Hibernation Therapeutics Ltd Stoppen, schützen und konservieren von organen
US6403567B1 (en) 1999-06-22 2002-06-11 Cv Therapeutics, Inc. N-pyrazole A2A adenosine receptor agonists
USRE47351E1 (en) 1999-06-22 2019-04-16 Gilead Sciences, Inc. 2-(N-pyrazolo)adenosines with application as adenosine A2A receptor agonists
WO2001062979A2 (en) 2000-02-23 2001-08-30 Cv Therapeutics, Inc. Dentification of partial agonists of the a2a adenosine receptor
US7157440B2 (en) * 2001-07-13 2007-01-02 Cv Therapeutics, Inc. Partial and full agonists of A1 adenosine receptors
US7713946B2 (en) 2002-07-11 2010-05-11 Cv Therapeutics, Inc. Partial and full agonists A1 adenosine receptors
JP2005530736A (ja) * 2002-04-18 2005-10-13 シーブイ・セラピューティクス・インコーポレイテッド ベーターブロッカー、カルシウムチャネルブロッカー、または心臓のグリコシドと共にａ１アデノシンアゴニストを投与することを含む不整脈の処置方法
US8470801B2 (en) 2002-07-29 2013-06-25 Gilead Sciences, Inc. Myocardial perfusion imaging methods and compositions
GB2436255B (en) * 2002-12-23 2007-11-28 Global Cardiac Solutions Pty L Organ preconditioning, arrest, protection, preservation and recovery
WO2006017052A1 (en) * 2004-07-12 2006-02-16 Cv Therapeutics, Inc. Process for the preparation of a1 adenosine receptor agonists
US20060019954A1 (en) * 2004-07-20 2006-01-26 Cedars-Sinai Medical Center Method for reducing the likelihood of the occurrence of cardiac arrhythmias
US7300923B2 (en) * 2004-08-30 2007-11-27 Cv Therapeutics, Inc. Partial and full agonists of A1 adenosine receptors
EP1802775B1 (en) 2004-09-14 2010-05-26 The Regents of the University of Colorado Method for treatment with bucindolol based on genetic targeting
US7822474B2 (en) * 2005-11-30 2010-10-26 Cedars-Sinai Medical Center Methods for the prediction of arrhythmias and prevention of sudden cardiac death
AU2007212542B2 (en) 2006-02-03 2013-01-31 Gilead Sciences, Inc. Process for preparing an A2A-Adenosine receptor agonist and its polymorphs
EP2079301B1 (en) 2006-05-29 2017-03-15 Hibernation Therapeutics, a KF LLC Improved tissue maintenance
EP2139316B1 (en) 2006-07-25 2015-03-18 Hibernation Therapeutics, a KF LLC Trauma therapy
US20100119554A1 (en) 2007-03-02 2010-05-13 Hibernation Therapeutics Limited Transplants
PT2234614E (pt) * 2007-12-21 2013-01-25 Aop Orphan Pharmaceuticals Ag Composição farmacológica para administração parenteral de um antagonista beta-adrenorreceptor de eficácia ultra rápida
US20100086483A1 (en) * 2008-09-29 2010-04-08 Gilead Palo Alto, Inc. Method of multidetector computed tomagraphy
GB0903299D0 (en) * 2009-02-26 2009-04-08 Guys And St Thomas Nhs Foundat Composition and methods
CA2835771C (en) * 2009-03-18 2017-01-24 Incarda Therapeutics, Inc. Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration
WO2011019752A2 (en) 2009-08-14 2011-02-17 Gilead Palo Alto, Inc. A1 adenosine receptor agonist polymorphs
EP2523669B1 (en) 2010-01-11 2016-12-07 Inotek Pharmaceuticals Corporation Combination, kit and method of reducing intraocular pressure
PT2555776T (pt) 2010-03-19 2017-02-01 Inotek Pharmaceuticals Corp Composições de combinação de agonistas de adenosina a1 e bloqueadores não selectivos dos receptores adrenérgicos beta para redução da pressão intra-ocular
AU2011230580A1 (en) 2010-03-26 2012-10-11 Inotek Pharmaceuticals Corporation Method of reducing intraocular pressure in humans using N6 -cyclopentyladenosine (CPA), CPA derivatives or prodrugs thereof
US20120005128A1 (en) * 2010-06-29 2012-01-05 Sanofi Methods for reducing the risk of an adverse dronedarone / calcium channel blockers interaction in a patient suffering from atrial fibrilation
PL2807178T3 (pl) 2012-01-26 2017-12-29 Inotek Pharmaceuticals Corporation Bezwodne polimorfy azotanu (2R,3S,4R,5R)-5-(6-(cyklopentyloamino)-9H-puryn-9-ylo)-3,4-dihydroksytetrahydrofuran-2-ylo)metylu i sposoby ich wytwarzania
MX2015013234A (es) 2013-03-15 2016-04-15 Inotek Pharmaceuticals Corp Formulaciones oftalmicas.
CN105705151A (zh) 2013-07-17 2016-06-22 低温药理Kf有限公司 一种用于治疗出血、休克和脑损伤的方法
AU2014361813A1 (en) * 2013-12-13 2016-07-28 Ralph ANKENMAN Compositions and methods for treating dysregulated systems
KR20180102201A (ko) 2016-02-01 2018-09-14 인카다 테라퓨틱스, 인크. 심방 세동을 포함한 심장 부정맥을 관리하기 위한 전자 모니터링과 흡입 약리 치료의 조합
CN106370754B (zh) * 2016-11-07 2019-03-08 西安科技大学 基于手性高效液相色谱-质谱/质谱技术定量检测布新洛尔光学异构体含量的方法
WO2018209107A1 (en) 2017-05-10 2018-11-15 Incarda Therapeutics, Inc. Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration
WO2019183470A2 (en) 2018-03-22 2019-09-26 Incarda Therapeutics, Inc. A novel method to slow ventricular rate
US10799138B2 (en) 2018-04-05 2020-10-13 University Of Maryland, Baltimore Method of administering sotalol IV/switch
US11610660B1 (en) 2021-08-20 2023-03-21 AltaThera Pharmaceuticals LLC Antiarrhythmic drug dosing methods, medical devices, and systems
US10512620B1 (en) 2018-08-14 2019-12-24 AltaThera Pharmaceuticals, LLC Method of initiating and escalating sotalol hydrochloride dosing
US11344518B2 (en) 2018-08-14 2022-05-31 AltaThera Pharmaceuticals LLC Method of converting atrial fibrillation to normal sinus rhythm and loading oral sotalol in a shortened time frame
US11696902B2 (en) 2018-08-14 2023-07-11 AltaThera Pharmaceuticals, LLC Method of initiating and escalating sotalol hydrochloride dosing
JP7156154B2 (ja) * 2019-04-18 2022-10-19 株式会社島津製作所 培地処理システム及び培地処理方法
US11007185B2 (en) 2019-08-01 2021-05-18 Incarda Therapeutics, Inc. Antiarrhythmic formulation

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5108363A (en) * 1988-02-19 1992-04-28 Gensia Pharmaceuticals, Inc. Diagnosis, evaluation and treatment of coronary artery disease by exercise simulation using closed loop drug delivery of an exercise simulating agent beta agonist
US5736528A (en) * 1993-10-28 1998-04-07 University Of Florida Research Foundation, Inc. N6 -(epoxynorborn-2-yl) adenosines as A1 adenosine receptor agonists
AU722110B2 (en) * 1996-06-28 2000-07-20 Merck & Co., Inc. Pharmaceutical preparation
US5789416B1 (en) * 1996-08-27 1999-10-05 Cv Therapeutics Inc N6 mono heterocyclic substituted adenosine derivatives
ES2178157T3 (es) * 1997-01-31 2002-12-16 Univ Leland Stanford Junior Tratamiento de arritmias mediante la inhibicion de una proteina quinasa multifuncional dependiente de calcio/calmodulina.
CO5180581A1 (es) 1999-09-30 2002-07-30 Pfizer Prod Inc Compuestos para el tratamiento de la isquemia ciones farmaceuticas que los contienen para el tratamiento de la isquemia
WO2001040799A2 (en) * 1999-12-03 2001-06-07 Cv Therapeutics, Inc. Method of identifying partial adenosine a1 receptor agonists and their use in the treatment of arrhythmias
US6605597B1 (en) * 1999-12-03 2003-08-12 Cv Therapeutics, Inc. Partial or full A1agonists-N-6 heterocyclic 5′-thio substituted adenosine derivatives
AU9259101A (en) * 2000-09-08 2002-03-22 Cv Therapeutics Inc Purine ribosides as antiarrhythmics
US6946449B2 (en) 2001-07-13 2005-09-20 Cv Therapeutics, Inc. Partial and full agonists of A1 adenosine receptors
JP2005530736A (ja) * 2002-04-18 2005-10-13 シーブイ・セラピューティクス・インコーポレイテッド ベーターブロッカー、カルシウムチャネルブロッカー、または心臓のグリコシドと共にａ１アデノシンアゴニストを投与することを含む不整脈の処置方法

Also Published As

Publication number Publication date
US20030216349A1 (en) 2003-11-20
CN101385738A (zh) 2009-03-18
EP1494685A1 (en) 2005-01-12
NZ536001A (en) 2006-05-26
JP2005530736A (ja) 2005-10-13
NO20045005L (no) 2004-11-17
WO2003088978A1 (en) 2003-10-30
CA2482928A1 (en) 2003-10-30
AU2003235466A1 (en) 2003-11-03
EP1494685B1 (en) 2008-12-31
KR20040106354A (ko) 2004-12-17
ZA200408411B (en) 2006-02-22
US7479485B2 (en) 2009-01-20
MXPA04010285A (es) 2005-02-03
US20060052333A1 (en) 2006-03-09
RU2332220C2 (ru) 2008-08-27
DE60325572D1 (de) 2009-02-12
ATE418991T1 (de) 2009-01-15
AU2003235466C1 (en) 2008-03-20
CN1646142A (zh) 2005-07-27
ES2318129T3 (es) 2009-05-01
US7005425B2 (en) 2006-02-28
US20090118221A1 (en) 2009-05-07
RU2004130826A (ru) 2005-05-10

Similar Documents

Publication Publication Date Title
IL164652A0 (en) Method of treating arrhythmias comprising administration of an A1 adenosine agonist with a beta blocker, calcium channel blocker or a cardiac glycoside
WO2004043377A3 (en) Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases
ZA200409388B (en) Methods and compositions using immunodulatory compounds for treatment and management of cancers and other diseases
WO2004103274A3 (en) Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases
ES2158778A1 (es) Compuestos de sales de paroxetina, su preparacion y uso, y composiciones farmaceuticas que los contienen.
EP0781136A4 (en) COMPOUNDS AND METHODS FOR TREATING CANCER
CA2146973A1 (en) Uses of tgf-.beta. receptor fragment as a therapeutic agent
WO2004006859A3 (en) Platinum compound
AU1810001A (en) Compounds, compositions, and methods for stimulating neuronal growth and elongation
HK1082663A1 (en) Extract with anti-tumor and anti-poisonous activity
MY129445A (en) Compositions for treating inflammatory response
AU2001292579A1 (en) Methods and compounds for treating proliferative diseases
WO2005046593A3 (en) Methods and compositions using thalidomide for the treatment and management of cancers and other diseases.
ES2088771A1 (es) Metodo para mejorar la acividad reproductora en verracos utilizando alimento para los verracos reproductores.
WO2004012746A3 (en) New uses for inhibitors of inosine monophosphate dehydrogenase
WO2001045684A3 (en) Formulations of adenosine a1 agonists
PL376346A1 (en) Alpha 2b 0r 2b/2c adrenoceptor agonists for the treatment of neurodegeneration
MXPA04005207A (es) Metodos para tratar cancer utilizando un inhibidor de la farnesil proteina transferasa y agentes antineoplasticos.
GB9924941D0 (en) Treatment of dyskinesia
EP1152760A4 (en) USE OF 4-AMINO PYRIDINE FOR THE TREATMENT OF PERIPHERAL NEUROPATHIES
WO2005094282B1 (en) Combination therapy comprising cloretazinetm
ZA988009B (en) Methods of administering an ampa receptor antagonist to treat dyskinesias associated with dopamine agonist therapy.
AU9259101A (en) Purine ribosides as antiarrhythmics
AU4937499A (en) Use of succinic acid or salts thereof and method of treating insulin resistance
WO2000061183A3 (en) Verotoxin treatment of lymphomas